People: OPKO Health Inc (OPK)
OPK on New York Consolidated
7.14USD
18 Jun 2013
7.14USD
18 Jun 2013
Price Change (% chg)
$0.07 (+0.99%)
$0.07 (+0.99%)
Prev Close
$7.07
$7.07
Open
$7.19
$7.19
Day's High
$7.29
$7.29
Day's Low
$7.10
$7.10
Volume
2,704,417
2,704,417
Avg. Vol
1,546,930
1,546,930
52-wk High
$7.83
$7.83
52-wk Low
$4.00
$4.00
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Phillip Frost |
67 | 2007 | Chairman of the Board, Chief Executive Officer |
Jane Hsiao |
65 | 2007 | Vice Chairman of the Board, Chief Technical Officer |
Juan Rodriguez |
39 | 2012 | Chief Financial Officer, Senior Vice President |
Steven Rubin |
52 | 2007 | Executive Vice President - Administration, Director |
Thomas Beier |
66 | 2008 | Director |
Robert Baron |
72 | 2003 | Independent Director |
Richard Lerner |
61 | 2007 | Independent Director |
John Paganelli |
77 | 2007 | Independent Director |
Richard Pfenniger |
57 | 2008 | Independent Director |
Lin-Tsing Yu |
68 | 2009 | Independent Director |
Biographies
| Name | Description |
|---|---|
Phillip Frost |
Dr. Phillip Frost M.D., is Chairman of the Board, Chief Executive Officer of Opko Health Inc upon the consummation of the merger of Acuity Pharmaceuticals Inc., Froptix Corporation and eXegenics, Inc. on March 27, 2007. Dr. Frost was named the Chairman of the Board of Teva Pharmaceutical Industries, Limited, or Teva, (NYSE:TEVA) in March 2010 and had previously been Vice Chairman since January 2006 when Teva acquired IVAX Corporation, or IVAX. Dr. Frost had served as Chairman of the Board of Directors and Chief Executive Officer of IVAX Corporation since 1987. He was Chairman of the Department of Dermatology at Mt. Sinai Medical Center of Greater Miami, Miami Beach, Florida from 1972 to 1986. Dr. Frost was Chairman of the Board of Directors of Key Pharmaceuticals, Inc. from 1972 until the acquisition of Key Pharmaceuticals by Schering Plough Corporation in 1986. Dr. Frost was named Chairman of the Board of Ladenburg Thalmann Financial Services Inc. (NYSE Amex:LTS), an investment banking, asset management, and securities brokerage firm providing services through its principal operating subsidiary, Ladenburg Thalmann & Co. Inc., in July 2006 and has been a director of Ladenburg Thalmann from 2001 until 2002 and again since 2004. Dr. Frost also serves as Chairman of the board of directors of PROLOR Biotech, Inc. (NYSE Amex: PBTH), a development stage biopharmaceutical company. He serves as a member of the Board of Trustees of the University of Miami and as a Trustee of each of the Scripps Research Institute, the Miami Jewish Home for the Aged, and the Mount Sinai Medical Center. Dr. Frost is also a director of Castle Brands (NYSE Amex:ROX), a developer and marketer of premium brand spirits. Dr. Frost previously served as a director for Continucare Corporation, Northrop Grumman Corp., Ideation Acquisition Corp., Protalix Bio Therapeutics, Inc., and SafeStitch Medical Inc., and as Governor and Co-Vice-Chairman of the American Stock Exchange (now NYSE Amex). |
Jane Hsiao |
Dr. Jane H. Hsiao, Ph.D. MBA, is Vice Chairman of the Board, Chief Technical Officer of Opko Health Inc since May 2007. Dr. Hsiao served as the Vice Chairman-Technical Affairs of IVAX from 1995 to January 2006. Dr. Hsiao served as Chairman, Chief Executive Officer and President of IVAX Animal Health, IVAX’s veterinary products subsidiary, from 1998 to 2006. Dr. Hsiao has served as Chairman of the Board of each of Safestitch Medical, Inc. (OTCQB:SFES) and Non-Invasive Monitoring Systems, Inc. (OTCBB:NIMU), both medical device companies, since September 2007 and October 2008, respectively, and was named Interim Chief Executive Officer of Non-Invasive Monitoring Systems, Inc. in February 2012. Dr. Hsiao is also a director of PROLOR Biotech, Inc. (NYSE Amex: PBTH), a development stage biopharmaceutical company, Sorrento Therapeutics, Inc. (OTCBB:SRNE), a development stage biopharmaceutical company, and Neovasc, Inc. (TSXV:NVC), a company developing and marketing medical specialty vascular devices. Dr. Hsiao previously served as a director for Protalix BioTherapeutics, Inc. |
Juan Rodriguez |
Mr. Juan F. Rodriguez has been appointed as Chief Financial Officer, Senior Vice President of OPKO Health, Inc., effective on July 16, 2012. Immediately prior to joining OPKO, Mr. Rodriguez, was serving as a consultant since 2007 to Cognitec Systems GmbH, a German software developer. From 1995 to 2007, prior to its acquisition by Abbott Laboratories, Mr. Rodriguez had been with Kos Pharmaceuticals, Inc., a publicly traded, specialty pharmaceutical company engaged in the development and commercialization of proprietary prescription products. During his approximately twelve years at Kos, Mr. Rodriguez held various positions of increasing responsibility, including serving as Interim Chief Financial Officer, and last serving as Senior Vice President, Controller and Corporate Administration. Prior to joining Kos, Mr. Rodriguez was employed by Arthur Andersen LLP from 1991 to 1994. Mr. Rodriguez has direct experience in all relevant financial disciplines, including transaction support (acquisitions, divestitures, strategic transactions, restructuring and capital markets), international corporate finance, treasury, accounting and control, business planning and analysis, tax, risk management, and corporate development. Mr. Rodriguez is a Certified Public Accountant and obtained his Bachelor of Accounting from Florida International University. |
Steven Rubin |
Mr. Steven D. Rubin, Esq., is Executive Vice President - Administration, Director of Opko Health Inc since May 2007. He served as a director of the Company since February 2007. Mr. Rubin served as the Senior Vice President, General Counsel and Secretary of IVAX from August 2001 until September 2006. Mr. Rubin currently serves on the board of directors of Dreams, Inc. (NYSE Amex:DRJ), a vertically integrated sports licensing and products company, Safestitch Medical, Inc. (OTCQB:SFES), a medical device company, Searchmedia Holdings, Ltd, (NYSEAmex:IDI), a nationwide multi-platform media company and one of the operators of integrated outdoor billboard and in-elevator advertising networks in China, PROLOR Biotech, Inc. (NYSE Amex: PBTH), a development stage biopharmaceutical company, Kidville, Inc. (OTCBB:KVIL), which operates , upscale facilities, catering to newborns through five-year-old children and their families and offers a wide range of developmental classes for newborns to 5 year olds, Non-Invasive Monitoring Systems, Inc. (OTCBB:NIMU), a medical device company, Tiger X Medical, Inc. (OTCBB:CDOM), previously an early-stage orthopedic medical device company specializing in designing, developing and marketing reconstructive joint devices and spinal surgical devices, Castle Brands, Inc. (NYSE Amex:ROX), a developer and marketer of premium brand spirits, and Neovasc, Inc. (TSXV:NVC), a company developing and marketing medical specialty vascular devices. |
Thomas Beier |
Mr. Thomas E. Beier is Director of Opko Health Inc since January 2008. Previously, he was Senior Vice President of Finance and Chief Financial Officer of IVAX from October 1997 until August 2007, and from December 1996 until October 1997, he served as Vice President-Finance for IVAX. Before joining IVAX, Mr. Beier served as Executive Vice President and Chief Financial Officer of Intercontinental Bank. Mr. Beier previously served as a director of Ideation Acquisition Corp. |
Robert Baron |
Mr. Robert A. Baron is Independent Director of Opko Health Inc since 2003. Mr. Baron is currently a director of Andover Medical, Inc. (Pink Sheets:ADOV.PK), a durable medical equipment distributor. Prior to that he was president of Cash City, Inc., a payday advance and check cashing business, from 1999 to 2003. From 1997 to 1999, Mr. Baron was the president of East coast operations for CSS/TSC, Inc., a distributor of blank t-shirts, fleece and accessories and a subsidiary of Tultex, Inc. Mr. Baron previously served as a director of Hemobiotech, Inc. and Nanosensors, Inc. |
Richard Lerner |
Professor Dr. Richard Alan Lerner, M.D., is Independent Director of Opko Health Inc since March 2007. Dr. Lerner served as President of The Scripps Research Institute, a private, non-profit biomedical research organization, from 1986 until 2011 and is currently serving as an institute professor. Dr. Lerner is a member of numerous scientific associations, including the National Academy of Science and the Royal Swedish Academy of Sciences. Dr. Lerner serves as director of Kraft Foods, Inc. (NYSE:KFT) and Sequenom, Inc. (Nasdaq:SQNM), a life sciences company. He is also on the board of directors for Intra-Cellular Therapies, a privately held biotechnology company. He previously served as a director of Xencor, a privately held biotechnology company, and on the Siemens’ Advisory Board for Molecular Medicine of Siemens AG. |
John Paganelli |
Mr. John A. Paganelli is Independent Director of Opko Health Inc since December 2003. Mr. Paganelli served as the Company’s Interim Chief Executive Officer and secretary from June 29, 2005 through March 27, 2007, and Chairman of Board of Directors from December 2003 through March 27, 2007. Mr. Paganelli served as President and Chief Executive Officer of Transamerica Life Insurance Company of New York from 1992 to 1997. Since 1987, Mr. Paganelli has been a partner in RFG Associates, a financial planning organization. Mr. Paganelli is also the Managing Partner of Pharos Systems Partners, LLC, an investment company, and he is Chairman of the Board of Pharos Systems International, a software company. He was Vice President and Executive Vice President of PEG Capital Management, an investment advisory organization, from 1987 until 2000. From 1980 to January 2003, Mr. Paganelli was an officer and director-stockholder of Mike Barnard Chevrolet, Inc., an automobile dealership. Mr. Paganelli also serves as a director of Western New York Energy, LLC and is on the Board of Trustees of Paul Smith’s College. Mr. Paganelli previously served on the Board of Managers of Bridge Financial Services, LLC. |
Richard Pfenniger |
Mr. Richard C. Pfenniger, Jr., is Independent Director of Opko Health Inc since January 2008. Mr. Pfenniger served as Chief Executive Officer and President for Continucare Corporation (NYSE:CNU), a provider of primary care physician and practice management services, from October 2003 until October 2011, and served as Chairman of the Board of Directors of Continucare from September 2002 until October 2011. Previously, Mr. Pfenniger served as the Chief Executive Officer and Vice Chairman of Whitman Education Group, Inc. from 1997 through June 2003. Prior to joining Whitman, he served as the Chief Operating Officer of IVAX from 1994 to 1997, and, from 1989 to 1994, he served as the Senior Vice President-Legal Affairs and General Counsel of IVAX Corporation. Mr. Pfenniger currently serves as a director of GP Strategies Corporation (NYSE:GPX), a corporate education and training company, and SafeStitch Medical, Inc. (OTCQB:SFES), a medical device company. |
Lin-Tsing Yu |
Dr. Lin-Tsing Yu, M.D., Ph.D., is Independent Director of Opko Health Inc since April 2009. Since 2003, Dr. Yu has served as Distinguished Research Fellow and Associate Director at the Genomics Research Center, Academia Sinica, in Taiwan. She has also served as a Professor of Pediatrics for both the National Taiwan University and University of California in San Diego, since 2004 and 1994, respectively. Previously, she was the Chief of Pediatric Hematology Oncology at the University of California in San Diego. Dr. Yu has also served in several government-appointed positions and is a member of numerous scientific committees and associations. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Phillip Frost |
469,800 |
Jane Hsiao |
459,800 |
Juan Rodriguez |
-- |
Steven Rubin |
359,800 |
Thomas Beier |
-- |
Robert Baron |
-- |
Richard Lerner |
-- |
John Paganelli |
158,796 |
Richard Pfenniger |
-- |
Lin-Tsing Yu |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Phillip Frost |
0 | 0 |
Jane Hsiao |
0 | 0 |
Juan Rodriguez |
0 | 0 |
Steven Rubin |
0 | 0 |
Thomas Beier |
0 | 0 |
Robert Baron |
0 | 0 |
Richard Lerner |
0 | 0 |
John Paganelli |
40,000 | 500 |
Richard Pfenniger |
0 | 0 |
Lin-Tsing Yu |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
PHILLIP FROST ET AL |
1,753 | $6.77 |
PHILLIP FROST ET AL |
1,247 | $6.78 |
PHILLIP FROST ET AL |
4,000 | $6.76 |
PHILLIP FROST ET AL |
100 | $6.47 |
PHILLIP FROST ET AL |
1,000 | $6.63 |
PHILLIP FROST ET AL |
300 | $6.54 |
PHILLIP FROST ET AL |
200 | $6.53 |
PHILLIP FROST ET AL |
1,000 | $6.48 |
PHILLIP FROST ET AL |
64,500 | $6.50 |
PHILLIP FROST ET AL |
5,984 | $6.51 |
PHILLIP FROST ET AL |
20,000 | $6.62 |
PHILLIP FROST ET AL |
4,400 | $6.49 |
PHILLIP FROST ET AL |
1,516 | $6.52 |
PHILLIP FROST ET AL |
1,000 | $6.57 |
PHILLIP FROST ET AL |
2,000 | $6.26 |
PHILLIP FROST ET AL |
12,300 | $6.29 |
PHILLIP FROST ET AL |
1,010 | $6.30 |
PHILLIP FROST ET AL |
5,975 | $6.42 |
PHILLIP FROST ET AL |
3,150 | $6.27 |
PHILLIP FROST ET AL |
100,000 | $6.31 |
PHILLIP FROST ET AL |
2,850 | $6.25 |
PHILLIP FROST ET AL |
11,200 | $6.54 |
PHILLIP FROST ET AL |
10,545 | $6.49 |
PHILLIP FROST ET AL |
3,375 | $6.38 |
PHILLIP FROST ET AL |
17,455 | $6.47 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
